Paediatric prescribing of asthma drugs in the UK: are we sticking to the guideline?

Simon Cohen, Jonny Taitz, Adam Jaffé

Background: Asthma guidelines should lead to improved, more rational asthma medication prescribing. The aims of this study were to assess trends in paediatric asthma drug prescribing in the UK and to assess the potential impact of the publication of the British Thoracic Society (BTS) asthma guideline.

Methods: The estimated community paediatric prescribing figures for asthma medications in the UK were studied using data from the NHS Information Centre for Health and Social Care for the years 2000–2006. Results: The numbers of prescriptions for bronchodilator syrups decreased by 60% from 2000 to 2006. However, this still represents 121,000 prescriptions for bronchodilator syrups in 2006 despite minimal recommendations for their use. The percentage of steroid inhalers prescribed as combination inhalers of a steroid and a long-acting β2 agonist increased from 2.6% in 2000 to 20.6% in 2006.

Conclusions: Steroid-alone inhalers should be the mainstay for the vast majority of patients with asthma who require controller medications. The increase in the number of combination inhalers prescribed is not consistent with the guideline recommendations that combination inhalers should only be introduced in those patients with asthma not controlled on adequate doses of inhaled steroids. Further education of health professionals is required.

METHODS

Data were obtained from the NHS Information Centre for Health and Social Care for all asthma medications for all years between 2000 and 2006. Information from Prescription Cost Analysis (PCA) provides details of the numbers of different prescriptions dispensed in the community in England. PCA data are based on information obtained from prescriptions sent to the Prescription Pricing Authority (PPA) for payment. Currently, PCA data cover all prescriptions dispensed in the community by community pharmacists, appliance contractors and dispensing doctors, and items personally administered by doctors. In the PCA data, 0–15-year olds are defined as children and 16–18-year olds as being in full-time education. This national database does not contain information stratified by age.

The vast majority of prescriptions included in these data were written by GPs in England. Prescriptions written by hospital doctors were also included provided that they were dispensed in the community. Prescriptions written in Wales, Scotland, Northern Ireland and the Isle of Man but dispensed in England were also included. Prescriptions written in England but dispensed outside England were not included.

The numbers of prescriptions for all bronchodilator syrups were summed for each year. The numbers of prescriptions for all combination inhalers of a long-acting β2 agonist (LABA) and a steroid were summed for each year. These consisted of all the available formulations of fluticasone/salmeterol or budesonide/formoterol combinations.

Total prescriptions for all the inhaled steroid-only preparations were extracted from the database and the percentage of steroid inhalers prescribed as combination inhalers calculated. All inhaled preparations with the steroids beclometasone, fluticasone, budesonide and mometasone were included in the capture.

Abbreviations: BTS, British Thoracic Society; GP, general medical practitioner; LABA, long-acting β2 agonist; LTRA, leukotriene antagonist; PCA, Prescription Cost Analysis; PPA, Prescription Pricing Authority; SIGN, Scottish Intercollegiate Guidelines Network
The other main groups of asthma medications were also totalled for each year. These included all forms of preparations containing xanthines (theophylline and aminophylline), leukotriene antagonists (LTRAs), sodium chromoglycates, LABAs (formoterol and salmeterol) and ipratropium bromide.

Population demographic data for the years 2000 and 2006 were obtained from the UK National Statistics website and extracted from the database provided.9

RESULTS
The number of prescriptions for bronchodilator syrups decreased steadily by 60% from 2000 to 2006. However, this still represents 121 000 prescriptions for bronchodilator syrups in 2006 (fig 1).

The total number of prescriptions for LABA has doubled from 258 000 prescriptions in 2000 to 505 000 in 2006.

There has been a steady rise in the number of combination steroid inhaler prescriptions, with prescription numbers in 2006 being over seven times those of 2000 (fig 1). The prescribing of steroid-alone inhalers has gradually declined from 2000 to 2006 as follows (thousands per year): 1968; 2036; 1945; 1744; 1642; 1609; 1525. The percentage of inhaled steroids prescribed as combination inhalers over this period were 2.6%, 5.2%, 7.8%, 11.2%, 14.3%, 18.0 and 20.6%, respectively. In 2006, there were 310 000 prescriptions for flixotide/serevent combination inhalers and 75 000 prescriptions for budesonide/formoterol inhalers.

The use of LTRA preparations has increased from 42 000 to 197 000 prescriptions, while there has been a steady decrease in all other classes of asthma drugs (fig 1).

The total number of prescriptions for LABAs has almost doubled over the 6-year period. The percentage of inhaled steroids prescribed as combination inhalers has increased from 2.6% to 20.6% from 2000 to 2006. According to the BTS guideline, LABAs are the first choice add-on therapy to inhaled steroids in adults and children aged 5–12 years, but they are not recommended in the youngest group aged <5 years. The pattern of asthma determines the need for preventive therapy and it is suggested in the guideline that a maximum dose of 400 µg/day of steroid (beclomethasone equivalent) is used before adding in a LABA for 5–12-year-old children, and 800 µg/day for adults.

A study of GP data in Australia attempted to outline the proportion of children belonging to the different categories.10 Infrequent episodic asthma was described as the most common pattern, accounting for 70–75% of children with asthma. This requires management of the individual episode only and regular preventive therapy is unnecessary. Frequent episodic asthma accounts for approximately 20% of childhood asthma. These two groups correspond to steps one and two of the BTS guideline and thus the vast majority of patients with asthma have mild intermittent or moderate asthma and should be managed with an inhaled short-acting β agonist only, with the addition of inhaled steroids or a leukotriene receptor antagonist for step two. Persistent asthma accounted for only 5–10% of childhood asthma. Despite this, the percentage of prescriptions for combined therapy was 20.6% of the total of steroid inhalers.

A limitation of this study is that it was not possible to obtain a further breakdown of these figures according to repeat prescriptions. However, it is likely that the rapid increase in the proportion of prescriptions for steroid-combination inhalers as opposed to steroid-only inhalers demonstrates a disproportionate use of these medications.

DISCUSSION
This study has shown that there has been a marked increase in the prescribing of LABA/steroid combination inhalers. Furthermore, there has been a steady decrease in the number of prescriptions for bronchodilator syrups, although they are still readily prescribed, with 121 000 prescriptions for syrups in 2006. This is a drug preparation that is of very little use in paediatric asthma management as the effect is more systemic compared to inhaled β agonists using a spacer device. The BTS guideline presents oral β agonist syrup as an option for children over 12 years old but points out that the inhaled route is preferable.4 These data suggest that oral β agonists are being prescribed outside their recommended use. However, it is reassuring that their use is declining.

The total number of prescriptions for LABAs has almost doubled over the 6-year period. The percentage of inhaled steroids prescribed as combination inhalers has increased from 2.6% to 20.6% from 2000 to 2006. According to the BTS guideline, LABAs are the first choice add-on therapy to inhaled steroids in adults and children aged 5–12 years, but they are not recommended in the youngest group aged <5 years. The pattern of asthma determines the need for preventive therapy and it is suggested in the guideline that a maximum dose of 400 µg/day of steroid (beclomethasone equivalent) is used before adding in a LABA for 5–12-year-old children, and 800 µg/day for adults.

A study of GP data in Australia attempted to outline the proportion of children belonging to the different categories.10 Frequent episodic asthma was described as the most common pattern, accounting for 70–75% of children with asthma. This requires management of the individual episode only and regular preventive therapy is unnecessary. Frequent episodic asthma accounts for approximately 20% of childhood asthma. These two groups correspond to steps one and two of the BTS guideline and thus the vast majority of patients with asthma have mild intermittent or moderate asthma and should be managed with an inhaled short-acting β agonist only, with the addition of inhaled steroids or a leukotriene receptor antagonist for step two. Persistent asthma accounted for only 5–10% of childhood asthma. Despite this, the percentage of prescriptions for combined therapy was 20.6% of the total of steroid inhalers.

A limitation of this study is that it was not possible to obtain a further breakdown of these figures according to repeat prescriptions. However, it is likely that the rapid increase in the proportion of prescriptions for steroid-combination inhalers as opposed to steroid-only inhalers demonstrates a disproportionate use of these medications.

Since the guideline was released, there have been an increasing number of reports suggesting that treatment with LABAs may be associated with increased severe and life-threatening asthma exacerbations as well as asthma-related deaths.11 12 A recent meta-analysis of 19 randomised, placebo-controlled clinical trials of LABAs published between 1966 and 2005 in which more than 30 000 children and adults with asthma participated, demonstrated an association between treatment with salmeterol and an increase in hospitalisations (OR 3.9) and an increase in the overall risk for asthma-related deaths in adults and children (OR 3.5).11

It has been suggested that more emphasis should be placed on the careful monitoring of patients who do not respond to or whose condition deteriorates in response to LABA therapy. The BTS guideline revision of November 2005 recommends a careful review of asthma control following LABA add-on therapy and suggests a different therapy should be tried if control is inadequate.15

As regards other asthma medication, the most striking change has been the nearly fivefold increase in the prescription rate for LTRA drugs from 2000 to 2006. These were first recommended in the 1993 BTS guideline and are currently advised as an optional first-line preventer drug or as add-on therapy. Furthermore, montelukast is being used increasingly for wheezy phenotypes, such as viral induced wheeze, and for exercised-induced asthma, or intermittently in asthma, which
In summary, we believe that these numbers point to an overuse of oral β agonists and LABA/steroid combination preparations in children as a group.

It is difficult to comment on the direct impact of the BTS guideline. However, our data suggest that prescribing in the community deviates from the guideline. There is a trend towards less prescribing of β agonist syrups, but the increase in combination products is not guideline driven. Therefore, these data support the implementation of measures to increase awareness of the guideline. Furthermore, this study has highlighted the need to gather information stratified by age in order to ensure adequate monitoring of prescribing practices.

ACKNOWLEDGEMENTS
The authors wish to acknowledge and thank Glen Scrivener from the Information Centre for supplying the data.

Authors’ affiliations
Simon Cohen, Jonny Taitz, Adam Jaffé, Sydney Children’s Hospital and University of New South Wales, High Street, Randwick, NSW 2031, Australia
Adam Jaffé, Portex Respiratory Unit, Institute of Child Health, 30 Guilford St, London WC1N 1EH, UK

Funding: This study did not receive specific funding.

Competing interests: SC and JT have no competing interests to declare. AJ is on the medical advisory panel of MSD. AJ has received funding from GSK and AstaZenca in the past.

SC was involved in the conception of the paper and the interpretation of data. SC, AJ and JT were involved in drafting the article and revising it critically for important intellectual comment. Only the authors and acknowledged parties were involved in study inception, analysis and interpretation.

Ethics approval was not required.

Note on data: These data remain the sole and exclusive property of The Information Centre and may only be reproduced where there is explicit reference to the ownership of The Information Centre.

REFERENCES